VisionCare Eye Clinic Business Plan › Section 3 › Industry & Market Analysis

3.1 Global & Regional Ophthalmology Market Context

The global ophthalmology market is a structurally growing segment of
healthcare, driven by population ageing, chronic-disease expansion
(notably diabetes), technology-led diagnostic innovation, and rising
consumer willingness to pay for vision correction. The global
optometry-equipment market alone is estimated at USD 5.09 billion in
2025 and is forecast to reach USD 6.93 billion by 2030, representing a
compound annual growth rate (CAGR) of 6.35%. The World Health
Organization estimates that over 2.2 billion people globally suffer from
vision impairment, of whom nearly 1 billion experience preventable or
untreated conditions.

Within this global opportunity, the Middle East and Africa
ophthalmology sub-region is characterised by severe supply-demand
imbalances. Ophthalmologist-to-population ratios are materially below
WHO-recommended minimums; access to advanced diagnostics is concentrated
in metropolitan areas; and private capital is responding by establishing
mid-tier integrated facilities of precisely the VisionCare
archetype.

3.2 South African Eye Care Market — Size & Growth

South Africa is the most developed healthcare market in Sub-Saharan
Africa, with a dual public-private system and a well-established
regulatory architecture. The South Africa ophthalmic devices market
alone — a conservative proxy for device-adjacent eye-care service spend
— is expected to reach USD 248.64 million in 2025 and grow to USD 308.52
million by 2030 at a CAGR of 4.41%, according to Mordor
Intelligence.

Figure 1

This device-market growth is a leading indicator of service-line
expansion: every rand spent on OCT scanners, fundus cameras, and laser
platforms typically translates into an estimated four to five rands of
associated clinical service revenue over the life of the asset. Applied
to VisionCare’s equipment investment, this ratio implies a
clinical-service addressable market of USD 1.0–1.4 billion annually at
full utilisation, of which the Company seeks less than 0.3% of revenue
share by Year 5.

3.3 Disease Burden & Demand Drivers

The clinical case for investment is anchored in a substantial and
rising burden of ocular disease in South Africa. A systematic scoping
review and meta-analysis covering the period 2010–2020 (published in
2022) established that 2% of the South African population is blind and
12% suffer moderate-to-severe visual impairment. The leading causes have
remained stable across the decade, providing a predictable long-term
demand signal for eye-care services.

Figure 2

Four demand drivers are particularly material to VisionCare’s
long-range outlook:

Driver 1: Diabetes & Diabetic Retinopathy

South Africa has one of the highest diabetes prevalence rates in
Sub-Saharan Africa, with an estimated 4.2 million adults living with
diabetes mellitus. International Diabetes Federation data indicate that
approximately 30% of diabetics develop some form of diabetic retinopathy
within 20 years of diagnosis. This implies a standing addressable
population of approximately 1.25 million South Africans requiring annual
diabetic-retinopathy screening, of whom only a fraction currently access
it. In December 2021, Eyenuk launched a nationwide Diabetic Retinopathy
Screening Benefit in South Africa powered by its EyeArt AI system,
signalling both the clinical need and the payor willingness to reimburse
structured screening programmes.

Driver 2: Demographic Ageing

Cataract is the second-largest cause of visual impairment in South
Africa and a function of age. The over-60 population is projected to
grow from approximately 5.5 million in 2024 to over 8 million by 2035.
Cataract prevalence in the over-70 population exceeds 60% in most
epidemiological studies, and cataract extraction is among the most
cost-effective of all surgical interventions measured in
quality-adjusted life years per rand spent.

Driver 3: Digital-Device Myopia Epidemic

Time spent on screens has risen sharply across all age cohorts in the
post-pandemic period, with the strongest effect observed among children
and adolescents. Published studies in Southern Africa demonstrate rising
myopia incidence, creating a long-tail demand for paediatric optometry,
myopia-management lenses, and contact-lens fitting services — a segment
where optical retail chains historically under-serve children due to
extended chair-time requirements.

Driver 4: Under-Corrected Refractive Error

The single largest cause of moderate-to-severe visual impairment in
South Africa — accounting for 43% of cases — is uncorrected refractive
error: myopia, hyperopia, astigmatism, and presbyopia that have simply
never been examined and prescribed for. This is mechanically the easiest
problem to solve in all of ophthalmology. Every patient accessing a
comprehensive eye examination is a candidate for both clinical service
revenue and optical retail revenue within a single visit.

3.4 Private Healthcare & Medical Scheme Landscape

VisionCare’s primary revenue channel is the private-healthcare payor
pool. Approximately 15.8% of South Africans — 9.7 million people — were
members of medical schemes as of 2022. These beneficiaries are
distributed across population groups with pronounced skews that inform
site selection and marketing strategy:

Figure 3

The medical-scheme industry is consolidated at the top: the ten
largest schemes together account for more than 80% of beneficiaries.
Discovery Health leads with approximately 2.76 million beneficiaries
(31.7% of the industry), followed by the restricted Government Employees
Medical Scheme (GEMS) with 1.92 million. Bonitas, Momentum Health,
Medihelp, Fedhealth, and Bestmed complete the top tier of open
schemes.

Figure 4

For a private eye clinic, the commercial implication is unambiguous:
ten scheme contract negotiations cover substantially all the private-pay
lives in the country. VisionCare’s business-development priority in the
first six months of operations is to secure Designated Service Provider
(DSP) or preferred-provider status with Discovery Health, Bonitas,
Momentum, and Fedhealth — a sequence that, once complete, makes the
Company the default in-network eye-care option for over 60% of all
medical-scheme beneficiaries in its catchment.

Medical Inflation and Tariff Pressure

The private-healthcare funding industry in South Africa is under
growing strain due to rising costs of private healthcare, slow economic
growth, and persistent medical inflation exceeding CPI. Less than 15% of
South Africans were covered by medical schemes in 2023, down from 16% in
2000. These pressures shape VisionCare’s pricing strategy toward
tariff-aligned fees that remain competitive against scheme reference
tariffs while capturing a premium for integrated service delivery and
shortened patient journey times. The tariff discipline embedded in
VisionCare’s financial model — 8% annual tariff escalation versus 7%
cost escalation — is consistent with observable sector behaviour.

3.5 Regulatory & Policy Environment

HPCSA and Clinical Registration

The Health Professions Council of South Africa (HPCSA) is the
statutory body regulating all health professionals, including
ophthalmologists, optometrists, dispensing opticians, and ophthalmic
nurses. HPCSA data indicate approximately 3,697 optometrists registered
in South Africa — an optometrist-to-population ratio of approximately
1:15,000, materially below the WHO-recommended minimum of 1:100,000 but
only because of concentration in urban areas. In rural and peri-urban
districts the effective ratio falls below 1:50,000. The ophthalmologist
population is smaller still: fewer than 500 registered ophthalmologists
serve the entire country, with approximately 113 employed in the public
sector serving roughly 52 million uninsured citizens.

Council for Medical Schemes (CMS) and Prescribed Minimum Benefits

Under the Medical Schemes Act 131 of 1998, all schemes are required
to cover a set list of conditions known as Prescribed Minimum Benefits
(PMBs). PMBs relevant to eye-care include cataract surgery, glaucoma
management, retinal detachment, and emergency ocular trauma. The PMB
framework is a contractual backstop that ensures VisionCare has a
minimum revenue floor per eligible patient regardless of benefit-option
restrictions the member may face.

National Health Insurance (NHI)

The NHI Act was signed into law in 2024, but its operationalisation
remains in a transitional phase with material uncertainty regarding the
future role of medical schemes, accredited provider status, and
tariff-setting mechanisms. VisionCare’s investment thesis is resilient
to several NHI outcomes: (i) if medical schemes continue as
complementary funders, the existing private-pay model remains intact;
(ii) if NHI becomes the dominant purchaser of healthcare services,
VisionCare’s accredited-provider status, clinical governance
documentation, and digital records systems position the Company well to
contract as an in-network provider; (iii) a prolonged policy-uncertainty
scenario is neutral-to-positive for existing operators because new
entrants will defer investment. The Company’s risk matrix (Section 9)
quantifies NHI scenarios explicitly.

Protection of Personal Information Act (POPIA)

As a custodian of sensitive health information, VisionCare will
register as a responsible party with the Information Regulator,
designate an Information Officer, implement a comprehensive
POPIA-compliance manual and Promotion of Access to Information Act
(PAIA) manual, and ensure its Electronic Medical Records (EMR) system is
compliant with the Act’s Eight Conditions for Lawful Processing. All
patient-consent forms will incorporate explicit consent for processing
of special personal information.

Confidential — this business plan is provided to prospective investors and lenders for evaluation purposes only and may not be reproduced or distributed without the written consent of VisionCare Eye Clinic (Pty) Ltd.